Muki Rapp

Director Técnico/Científico/I+D en Notal Vision Ltd. .

Health Services

Consumer Services

Perfil

Muki Rapp is currently the Vice President of Research & Development at Notal Vision Ltd.
He received his undergraduate, graduate, and doctorate degrees from The Hebrew University of Jerusalem.

Cargos activos de Muki Rapp

Empresas	Cargo	Inicio
Notal Vision Ltd. Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel.	Director Técnico/Científico/I+D	-

Todos los cargos activos de Muki Rapp

Formación de Muki Rapp.

The Hebrew University of Jerusalem

Doctorate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Muki Rapp.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	1
Notal Vision Ltd. Notal Vision Ltd. Medical/Nursing ServicesHealth Services Notal Vision Ltd. develops and manufactures computerized ophthalmic diagnostic devices. It develops age-related macular degeneration (AMD) monitor for patients at risk of vision loss from the devastating effects of wet AMD. The firm provides Preferential Hyperacuity Perimetry, a technology with clinical data for monitoring patients with AMD to eye care professionals. Its products are used for the detection and characterization of central and paracentral metamorphopsia in patients as an aid in monitoring progression of disease factors causing metamorphopsia, such as choroidal neovascularization. The company was founded in 2000 by Barak Azmon and Yair Alster and is headquartered in Tel Aviv, Israel.	Health Services